UK health authorities are investigating a potential link between weight loss and diabetes drugs and cases of acute pancreatitis. Nearly 400 reports of pancreas inflammation have been submitted to the UK’s Yellow Card scheme, which monitors adverse drug reactions. Most cases involve medications used for diabetes and weight loss, such as Mounjaro (tirzepatide), Wegovy and Ozempic (semaglutide), and liraglutide. Acute pancreatitis, a potentially serious condition, is listed as an “uncommon” side effect, but cases have risen alongside increased drug usage in 2025. The Medicines and Healthcare products Regulatory Agency (MHRA) is launching a study to explore possible genetic factors by inviting affected patients to participate in the Yellow Card Biobank. Pharmaceutical companies involved have emphasized patient safety and encouraged the use of these medications only under medical supervision.
Antonio De Corso
